<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain>We treated 12 patients with <z:hpo ids='HP_0001909'>leukemia</z:hpo> relapse after allogenic bone marrow transplantation with a combination of interferon-alpha (IFN-alpha) ((2.5-5.0) x 10(6) u/m2 subcutaneously three times a week) and interleukin-2 (IL-2) ((1.8-3.6) x 10(6) IU/m2 subcutaneously five times a week) to determine the toxicity and efficacy of combination cytokine therapy in this setting </plain></SENT>
<SENT sid="1" pm="."><plain>The median age of the patients was 39 years (range: 16-50) </plain></SENT>
<SENT sid="2" pm="."><plain>There were nine females and three males </plain></SENT>
<SENT sid="3" pm="."><plain>The median time to relapse from BMT was 98 days (range: 0-963) </plain></SENT>
<SENT sid="4" pm="."><plain>At the time of relapse, six patients had <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e>, four patients had <z:mp ids='MP_0005481'>CML</z:mp> (two in <z:e sem="disease" ids="C0005699" disease_type="Neoplastic Process" abbrv="">blast crisis</z:e> and two in <z:hpo ids='HP_0011010'>chronic</z:hpo> phase with <z:e sem="disease" ids="C1516669" disease_type="Neoplastic Process" abbrv="">clonal evolution</z:e>), and one patient had lymphoblastic <z:hpo ids='HP_0002665'>lymphoma</z:hpo> </plain></SENT>
<SENT sid="5" pm="."><plain>Combination cytokine therapy was started a median of 108 days post BMT (range: 37-2404) </plain></SENT>
<SENT sid="6" pm="."><plain>Nine patients treated at the higher dose level required a 50% dose reduction because of toxicity or GVHD (three <z:chebi fb="7" ids="29425,29426,29441,29447">CNS</z:chebi>, two GVHD, one high <z:hpo ids='HP_0001945'>fever</z:hpo>, one diarrhoea with <z:hpo ids='HP_0002615'>hypotension</z:hpo>, and one <z:hpo ids='HP_0001701'>pericarditis</z:hpo>) </plain></SENT>
<SENT sid="7" pm="."><plain>At a lower dose level, 2 of 10 patients had their treatment discontinued because of toxicity or GVHD </plain></SENT>
<SENT sid="8" pm="."><plain>Six patients developed clinical findings consistent with <z:hpo ids='HP_0011009'>acute</z:hpo> GVHD while on combination cytokine therapy </plain></SENT>
<SENT sid="9" pm="."><plain>Two patients responded to combination cytokine therapy: one with <z:mp ids='MP_0005481'>CML</z:mp> and one with <z:e sem="disease" ids="AmbiguousAbbrv" disease_type="AmbiguousAbbrv" abbrv="ambiguous">AML</z:e> </plain></SENT>
<SENT sid="10" pm="."><plain>Combination cytokine therapy is feasible in the setting of relapse post allogeneic BMT </plain></SENT>
<SENT sid="11" pm="."><plain>The combination of IL-2 1.8 x 10(6) IU/m2 five times a week with IFN-2 2.5 x 10(6) U/m2 three times a week seems to be tolerable, and merits further study in this setting </plain></SENT>
</text></document>